Zuccatosta Lina, Latini Letizia, Belleggia Beatrice, Gonnelli Francesca, Barbisan Francesca, Goteri Gaia, Gasparini Stefano, Marchetti Antonio
Pulmonary Diseases Unit, Azienda "Ospedali Riuniti", Ancona, Italy.
Department of Biomedical Sciences and Public Health, Polytechnic University of Marche Region, Ancona, Italy.
Front Med (Lausanne). 2023 Jan 12;9:1087028. doi: 10.3389/fmed.2022.1087028. eCollection 2022.
Transbronchial needle aspiration (TBNA) is a sampling tool that has demonstrated a higher accuracy in the diagnosis of peripheral pulmonary lesions (PPL) compared to other techniques. However, there are no studies investigating the value of TBNA in defining the genotype of peripheral lung cancer.
To evaluate the accuracy of TBNA in defining the molecular characteristics of peripheral lung cancer.
Consecutive patients who underwent TBNA for the diagnosis of a PPL at the Pulmonary Unit of the Azienda Ospedali Riuniti of Ancona (Italy) between January 2020 and September 2022 were included in the study. TBNA was performed under fluoroscopic guidance and the additional support of an ultrasound miniprobe, with an ultrathin bronchoscope with a flexible 21G needle. Samples were smeared on glass slides for cytological evaluation and flushed in 10% neutral-buffered formalin for cell-blocks.
154 patients were enrolled:55 were diagnosed with adenocarcinoma and 21 with squamous cell carcinoma. TBNA correctly diagnosed 43/55 (78.2%) patients with adenocarcinoma and 17/21 (81.0%) patients with squamous cell carcinoma, with a sensitivity of 77.5%. Complete genotyping for guiding targeted therapies was obtained in 52 patients (86.6%).
TBNA is a valid tool for the diagnosis of PPL, allowing a correct diagnosis and a complete genotyping of the tumors in a considerable proportion of patients.
经支气管针吸活检（TBNA）是一种采样工具，与其他技术相比，它在诊断周围型肺部病变（PPL）方面具有更高的准确性。然而，尚无研究探讨TBNA在确定周围型肺癌基因型方面的价值。
评估TBNA在确定周围型肺癌分子特征方面的准确性。
纳入2020年1月至2022年9月期间在意大利安科纳综合医院肺病科因诊断PPL而接受TBNA的连续患者。TBNA在荧光镜引导下并在超声微型探头的辅助下，使用带有可弯曲21G针的超细支气管镜进行。样本涂抹在载玻片上进行细胞学评估，并冲洗到10%中性缓冲福尔马林中制成细胞块。
共纳入154例患者：55例诊断为腺癌，21例诊断为鳞状细胞癌。TBNA正确诊断出43/55（78.2%）例腺癌患者和17/21（81.0%）例鳞状细胞癌患者，敏感性为77.5%。52例患者（86.6%）获得了用于指导靶向治疗的完整基因分型。
TBNA是诊断PPL的有效工具，在相当比例的患者中能够正确诊断肿瘤并获得完整的基因分型。
